This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Improving Aspirin Use in Diabetes: A Cluster Randomized Trial

This study has been completed.
Information provided by:
Northwestern University Identifier:
First received: December 5, 2005
Last updated: July 21, 2010
Last verified: July 2010
Our aim is to determine if a patient-directed intervention is more effective than computerized clinician reminders alone for improving aspirin use in adults with diabetes.

Condition Intervention
Diabetes Mellitus Behavioral: Electronic prompt plus patient-directed intervention Behavioral: Electronic prompt to clinician to prescribe aspirin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Improving Appropriate Aspirin Use Among Adults With Diabetes in a Primary Care Setting: Using an Electronic Medical Record to Target a Physician-supervised Nurse Practitioner Intervention

Resource links provided by NLM:

Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Patient reported aspirin use daily or every other day.

Estimated Enrollment: 300
Study Start Date: September 2004
Estimated Study Completion Date: May 2005
Detailed Description:

Many patients with diabetes do not use aspirin to prevent cardiovascular events. Quality improvement initiatives involving both patients and physicians may be more effective than physician-directed approaches alone.

In a large urban primary care internal medicine practice, this study seeks to test if a patient-directed intervention is more effective than computerized clinician reminders alone for improving the appropriate use of aspirin in adults with diabetes.

The study design is a cluster-randomized trial by physician. The frequency of self-reported regular aspirin use will be compared between patients cared for by physicians in the computerized reminder alone group and the computerized reminder plus physician-supervised, nurse practitioner intervention group.


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Diabetes mellitus

  • Age at least 40 years old
  • At least 2 clinic visits in the 18 months prior to the intervention

Exclusion Criteria:

  • Primary care physician declined enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00262977

United States, Illinois
Northwestern University, Division of General Internal Medicine
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Principal Investigator: Stephen D Persell, MD, MPH Northwestern University
  More Information Identifier: NCT00262977     History of Changes
Other Study ID Numbers: 1402-001
Study First Received: December 5, 2005
Last Updated: July 21, 2010

Keywords provided by Northwestern University:
diabetes mellitus
cardiovascular diseases
quality of healthcare

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics processed this record on August 23, 2017